Sodium-glucose co-transporter 2 inhibitors in heart failure: an updated evidence-based practical guidance for clinicians - Université de Lorraine Accéder directement au contenu
Article Dans Une Revue European Heart Journal Supplements Année : 2023

Sodium-glucose co-transporter 2 inhibitors in heart failure: an updated evidence-based practical guidance for clinicians

Résumé

The sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to reduce risks of clinical events in patients with heart failure (HF), with early and sustained benefits regardless of ejection fraction, diabetic status, and care setting. As part and parcel of the modern foundational HF therapy, clinicians should be familiar with these drugs, in order to implement their use and limit the potential adverse effects. We present an up-to-date review of current evidence and a practical guide for the prescription of SGLT2 inhibitors in patients with HF, highlighting important elements for patient selection, treatment initiation, dosing, and problem solving.
Fichier principal
Vignette du fichier
suad055.pdf (519 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04087732 , version 1 (03-05-2023)

Licence

Identifiants

Citer

Luca Monzo, Ilaria Ferrari, Francesco Cicogna, Claudia Tota, Gennaro Cice, et al.. Sodium-glucose co-transporter 2 inhibitors in heart failure: an updated evidence-based practical guidance for clinicians. European Heart Journal Supplements, 2023, 25 (Supplement C), pp.C309 - C315. ⟨10.1093/eurheartjsupp/suad055⟩. ⟨hal-04087732⟩
34 Consultations
49 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More